Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
22 Januar 2025 - 12:23PM
UK Regulatory
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Company Announcement
- Net sales of
DARZALEX® in 2024
totaled USD 11,670 million
- Genmab receives royalties on worldwide net sales from
Johnson & Johnson (J&J, legal entity Janssen Biotech,
Inc.)
COPENHAGEN, Denmark; January 22, 2025 –
Genmab A/S (Nasdaq: GMAB) announced today
that worldwide net trade sales of DARZALEX (daratumumab),
including sales of the subcutaneous (SC) product
(daratumumab and
hyaluronidase-fihj, sold under the tradename
DARZALEX
FASPRO®
in the U.S.),
as reported by J&J were USD 11,670 million in
2024. Net trade sales were USD 6,588 million in the U.S.
and USD 5,082 million in the rest of the world. Genmab receives
royalties on the worldwide net sales of DARZALEX, both the
intravenous and SC products, under the exclusive worldwide license
to J&J to develop, manufacture and commercialize
daratumumab.
About Genmab
Genmab is an international biotechnology company with a core
purpose of guiding its unstoppable team to strive toward improving
the lives of patients with innovative and differentiated antibody
therapeutics. For more than 25 years, its passionate, innovative
and collaborative team has invented next-generation antibody
technology platforms and leveraged translational, quantitative and
data sciences, resulting in a proprietary pipeline including
bispecific T-cell engagers, antibody-drug conjugates,
next-generation immune checkpoint modulators and effector
function-enhanced antibodies. By 2030, Genmab’s vision is to
transform the lives of people with cancer and other serious
diseases with knock-your-socks-off (KYSO) antibody
medicines®.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors
included in Genmab’s most recent Annual Report on Form 20-F and
other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at
www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following
trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination
with the Y-shaped Genmab logo®;
HuMax®;
DuoBody®;
HexaBody®;
DuoHexaBody®,
HexElect® and
KYSO®.
DARZALEX® and DARZALEX
FASPRO® are trademarks of Johnson
& Johnson.
Company Announcement no. 01
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
- 220125_CA01_DARZALEX FY 2024 sales
Genmab AS (TG:GE9)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Genmab AS (TG:GE9)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
